Gestational diabetes mellitus in a cohort of HIV-1 infected women

HIV Medicine

Volumn 9, Issue 10, 2008, Pages 868-874

  González Tomé, Maria Isabel ^a   Ramos Amador, J T ^b   Guillen, S ^b   Solis I ^b   Fernandez Ibieta M ^b   Munoz E ^a   Almeda, J ^c   Rojano, X ^c   Rojo, P ^a   Nieto, O ^a   Jimenez J S ^a   Pulido, F ^a   Rubio, R ^a   Ruiz Contreras, J ^a   Hernandez Garcia J M ^a   Ferrando, P ^a   Lora, D ^a   de la Cámara, A Gómez ^a   Regidor, F ^d   Espinola, G ^d   Del Barrio, P ^b   Iglesias, E ^b   Rubio, B ^b   Prieto, L ^b   Navarro, M L ^e   Saavedra, J ^e   Miralles, P ^e   Berenguer, J ^e   Gurbindo, M D ^e   Munoz M A ^e   Segovia, P ^e   de Jose M I ^f   Pena J M ^f   Salas, S ^f   Bates, I ^f   Santos, M J ^g   Goya, N N ^g   Calvo, C ^g   Roa, M A ^h   Garaulet, C ^h   Beceiro, J ⁱ   Onate S ⁱ   Casabona, J ^c   Garcia Fructuoso M T ^c   Fortuny, C ^j   Noguera, A ^j   Boguna J M ^j   Soler, P ^k   Garcia L ^k   Casellas, M ^k   Mur, A ^l   Paya A ^l   Rodrigo, C ^m   Grane N ^m   Sanchez E ⁿ   more..

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^c CEESCAT Center for Epidemiological Studies on HIV/AIDS of Catalonia   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f Hospital La Paz

^g HOSPITAL SEVERO OCHOA   (Spain)

^h HOSPITAL DE MÓSTOLES   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^j Hospital Sant Joan de Deu

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l HOSPITAL DEL MAR   (Spain)

^m Hospital Germans Trias y Pujol

ⁿ Agencia de Evaluación de Tecnología e Investigación Médicas

more..

Author keywords

Antiretroviral therapy; Gestational diabetes mellitus; HIV infection; Pregnancy; Protease inhibitor

Indexed keywords

DIDANOSINE; GLUCOSE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MIXED INFECTION; MONOTHERAPY; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THIRD TRIMESTER PREGNANCY; VIRUS LOAD;

EID: 55649099455     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00639.x     Document Type: Article

References (35)

1. Jimenez-Moleon JJ, Bueno-Cavanillas A, Luna-Del-Castillo JD et al. Prevalence of gestational diabetes mellitus: Variations related to screening strategy used. Eur J Endocrinol 2002; 146: 831-837.
2. Díez JJ, Grande C, Pallardo LF et al. Screening for gestational diabetes with the one hour 50g glucose test: Prevalence and relationship with risk factors. Med Clin (Barcelona) 1989; 93: 41-45.
3. Spanish Society of Gynaecology and Obstetricians. Perinatal data 2002. Available at http://www.sego.es
4. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitor associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 1998; 12: F167-F173.
5. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
6. Monier PL, Wilcox R. Metabolic complication associated with the use of highly active antiretroviral therapy in HIV-1-infected adults. Am Med Sci 2004; 328: 48-56.
7. Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; 42: 81-92.
8. Mehta SH, Moore RD, Thomas DL et al. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003; 33: 577-584.
9. Watts DH, Balasubramanian R, Maupin RT Jr et al. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004; 190: 506-516.
10. Aschkenazi S, Rochelson B, Bernasko J et al. Insulin resistance complicating pregnancy in a human immunodeficiency virus-infected patient treated with protease inhibitors and corticosteroids. Obstet Gynecol 2003; 102: 1210-1212.
11. Rosario P, Santos J, Ruiz J et al. Factors associated with the development of diabetes mellitus in HIV-infected patients on antiretroviral therapy: A case-control study. AIDS 2003; 17: 933-935.
12. Brambilla AM, Novati R, Calori G et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS 2003; 17: 1993-1995.
13. Dubé MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31: 1467-1475.
14. Justman JE, Benning L, Danoff A et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 298-302.
15. Danoff A, Shi Q, Justman J et al. Women's Interagency HIV Study (WIHS). Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. J Acquir Immune Defic Syndr 2005; 39: 55-62.
16. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
17. American College of Obstetricians and Gynecologists. Committee on Practice Bulletins - Obstetrics. Clinical management guidelines for obstetrician-gynecologists Number 30, September 2001 (Replaces Technical Bulletin Number 200, December 1994): Gestational Diabetes. Obstet Gynecol 2001; 98: 525-538.
18. Landon MB. Diabetes mellitus and other endocrine diseases, In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: Normal and Problems Pregnancies, 3rd edn. New York: Churchill-Livingstone, 1996: 1037-1081.
19. Nolte LA, Yarasheski KE, Kawanaka K et al. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes 2001; 50: 1397-1401.
20. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-20254.
21. Vigouroux C, Gharakhanian S, Salhi Y et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999; 25: 225-232.
22. Brown TT, Li X, Cole SR et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19: 1375-1383.
23. Lo JC, Kazemi MR, Hsue PY et al. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 2005; 41: 1335-1340.
24. Tuomala RE, Watts DH, Li D et al. Women and Infants Transmission Study. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38: 449-473.
25. Chmait R, Franklin P, Spector SA et al. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinatol 2002; 22: 370-373.
26. El Beitune P, Duarte G, Foss MC et al. Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women. Diabetes Metab Res Rev 2006; 22: 59-63.
27. Morris AB, Dobles AR, Cu-Uvin S et al. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr 2005; 40: 30-33.
28. Morris AB, Cu-Uvin S, Harwell JI et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr 2000; 25: 306-311.
29. Covadonga M, Peña JM, Bates I et al. Obstetric and perinatal complications in HIV-infected women. Analysis of a cohort of 167 pregnancies between 1997 and 2003. Acta Obstet Gynecol 2007; 86: 409-415.
30. Ricart W, Lopez J, Mozas J et al. Spanish Group for the Study of the Impact of Carpenter and Coustan GDM Thresholds. Potential impact of American Diabetes Association (2000) criteria for diagnosis of gestational diabetes mellitus in Spain. Diabetologia 2005; 48: 1135-1141.
31. Ricart W, Bach C, Fernandez-Real JM et al. Impact of a selective screening for gestational diabetes in a Spanish population. Med Clin (Barcelona) 1999; 113: 331-333.
32. Gorgojo Martínez JJ, Almodóvar Ruiz J, López Hernández E et al. Incidence of gestational diabetes mellitus according to different diagnostic criteria in the southeast Madrid area. Influence of diagnosis on materno-fetal parameters (In Spanish). Rev Clin Esp 2002; 202: 136-141.
33. Palacios R, Merchante N, Macias J et al. Incidence of and risk factors for insulin resistance in treatment-naïve HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther 2006; 11: 529-535.
34. Van der Valk M, Bisschop PH, Romijn JA et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001; 15: 2093-2100.
35. Dube MP. Lipodystrophy and insulin resistance in patients with HIV. J Acquir Immune Defic Syndr 2001; 27: 506-507.